Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2020-02-25 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "MONTELUKAST SODIUM TABLETS AND CHEWABLE TABLETS"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of certain pharmaceutical products. It is a short announcement (2690 characters) and does not contain financial data, financial statements, or detailed report content. It is not an annual report, interim report, earnings release, or any detailed financial or management report. It is also not a regulatory filing in the sense of compliance documents or certifications. The document is an announcement of a regulatory approval event related to the company's products, which fits best under the category of a general regulatory announcement. Given the lack of a more specific category for product approval announcements, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-02-25 English
INSIDE INFORMATION - PRELIMINARY RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2019
Earnings Release Classification · 95% confidence The document is an announcement of preliminary financial results for the year ended 31 December 2019 by CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited. It includes financial data and indicators, operating results, and explanations. However, it explicitly states that the data is preliminary and unaudited, and that the final audited data will be disclosed in the annual report. The document is titled as a "Preliminary Results Announcement" and is made pursuant to stock exchange rules for inside information disclosure. It is not a full annual report (10-K) but rather a financial results announcement with substantive financial data for the year. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results with key highlights. The document length (7285 characters) and content support this classification rather than a full Annual Report or Regulatory Filing. Therefore, the appropriate classification is Earnings Release (ER). FY 2019
2020-02-24 English
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG ALMB-0168 WAS GRANTED CLINICAL TRIAL APPROVAL IN AUSTRALIA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new investigational drug ALMB-0168 in Australia. It is an announcement of a regulatory milestone related to drug development, not a financial report, earnings release, or management discussion. The document is relatively short (3032 characters) and serves as a public disclosure of a significant event rather than a detailed report or presentation. It does not contain financial data, voting results, or management changes. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2020-02-24 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions for the month ended 31/01/2020. The document includes confirmations by a company director regarding compliance with listing rules and legal requirements. There are no financial statements, earnings data, or management discussion of financial results. The content focuses exclusively on share capital changes and related confirmations, which aligns with announcements about share capital changes rather than full financial reports or earnings releases. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (13,752 characters) and detailed data support it being a substantive report rather than a brief announcement or certification only.
2020-02-03 English
INSIDE INFORMATION - INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2019
Regulatory Filings Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the indicative results of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the year ended 31 December 2019. It is labeled as "indicative results" and explicitly states that the financial data has not been audited and is preliminary. The announcement references that the detailed and audited results will be disclosed in the company's annual report for 2019. The document is about preliminary financial results and is an announcement of inside information under Hong Kong Stock Exchange rules. It does not contain full audited financial statements or comprehensive financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a full Earnings Release (ER) since it provides a range and preliminary estimates rather than finalized quarterly or periodical results. Given the nature of the document as a preliminary financial results announcement and inside information disclosure, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (5220 characters) and content support this classification rather than a full financial report or earnings release.
2020-01-22 English
VOLUNTARY ANNOUNCEMENT - SELECTION RESULTS OF NATIONAL CENTRALISED MEDICINES PROCUREMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the selection results of their products in a national centralized medicines procurement tender in China. It provides specific details about product selection, pricing, and supplying provinces. The document is relatively short (2887 characters) and does not contain financial statements, management discussion, or regulatory certifications. It is an announcement of a business development event rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. The content is best classified as a general regulatory announcement about business operations, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2020-01-19 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.